March, 2009:

• NDA submitted for Stedesa as adjunctive epilepsy treatment
• Phase 2a study of KAI-1678 for neuropathic pain
• Phase 3 study of Urocidin for bladder cancer
• Phase 2 results of ZP-PTH for osteoporosis
• Phase 3 study of Ophena for postmenopausal vaginal atrophy
• Ixiaro, a vaccine to prevent Japanese Encephalitis
• Afinitor approved for advanced kidney cancer
• FDA fast track designation granted for SGN-35 for Hodgkin lymphoma
• Phase 2b study of dapagliflozin for type 2 diabetes
• FDA accepts sNDA for colorectal cancer indication for Fusilev
• Phase 3 study of LX211 (Luveniq) for uveitis
• NDA to be submitted for VIAject for the treatment of diabetes
• Phase 2 study of cicletanine for pulmonary arterial hypertension
• Tygacil gains indication for community-acquired bacterial pneumonia in adults
• Scalacort DK available for corticosteroid-responsive dermatoses
• Phase 3 study of farletuzumab for relapsed ovarian cancer
• Watson recalls propafenone HCl tablets
• FDA expands warning on tainted weight loss products
• Symbyax and Zyprexa gain indications
• Phase 2 study of NPI-2358 for non-small cell lung cancer
• Phase 2 study of adecatumumab for colorectal cancer
• Phase 3 study of arzoxifene for osteoporosis
• Phase 3 study of Exalgo for moderate-to-severe pain
• Lexapro approved for major depressive disorder in adolescents
• Zencore Plus dietary supplement recalled
• Locoid Lotion available in new size
• Shire issues recall of Daytrana patches
• FDA issues insulin pen and insulin cartridge warning
• Reclast approved for steroid-induced osteoporosis
• High Mortality for Certain Elderly Patients with Innohep
• Serious Skin Reactions in Asian Patients on Phenytoin and Fosphenytoin
• Supplemental NDA submitted for Tarceva as first-line maintenance therapy in advanced non-small cell lung cancer
• Phase 3 of MDV3100 for castration-resistant prostate cancer
• Phase 3 study of Myocet for metastatic breast cancer
• Phase 2 study of Nuvigil for bipolar depression
• Phase 2 study of budesonide/azelastine nasal spray for seasonal allergic rhinitis
• Phase 2b study of Transdur-sufentanil patch for chronic pain
• Phase 2 study of HP802-247 for venous leg ulcers
• Edluar approved for insomnia
• Aton Pharma acquires Timoptic product line
• Caution Using Topical Anesthetics Prior to Medical Procedures
• Propylthiouracil and Purinethol Mix-Ups
• Ephedrine and Epinephrine Mix-Ups
• Preventing Dosing Errors with Alteplase
• Uloric available for hyperuricemia
• Phase 3 Rituxan study fails to meet primary endpoint
• FDA accepts complete response submission to NDA for Nebido
• Scalpicin Anti-Itch Wipes launched
• Peg-Intron/Rebetol combination therapy gains expanded indication
• FC2 Female Condom approved
• New appearance for Topamax tablets
• Phase 1 study of PMX-60056 for heparin overdose
• Phase 1 study of AVN-211 for schizophrenia
• Phase 1b/2a study of AV-951 for non-small cell lung cancer
• ADXS11-001 for orphan drug designation
• Phase 2 Study of CPX-351 in acute myeloid leukemia
• FDA warns of transdermal drug patches
• AmLactin Foot Cream Therapy now available
• Degarelix available for prostate cancer
• Valstar approved for reintroduction into U.S. market
• FDA announces Consent Decree against KV Pharmaceuticals
• Copaxone gains expanded indication
• Avidoxy kit launched for acne
• Axona available for Alzheimer's disease
• Afrin PureSea nasal rinse available
• Symbicort approved for COPD
• FlexPen redesign launched